Drug lookup | Fillwise

Alertec · DIN 02239665 · 100mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptExceptional Access application required. For a drug to be considered for funding, the EAP reimbursement criteria must always be met and the request approved prior to the initiation of treatment with the drug being requested, unless otherwise specified within the criteria. (ontario.ca, Aug 31, 2026 ↗) Submit through SADIE: "The SADIE portal is available to authorized prescribers and their delegates and designates, enabling the creation, submission and tracking of web-based electronic requests directly to the Exceptional Access Program." (ontario.ca, Aug 31, 2026 ↗)

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Modafinil Brand(s): Alertec DOSAGE FORM/ STRENGTH: 100 mg tablet For the symptomatic treatment of excessive daytime sleepiness in patients with narcolepsy who have demonstrated a lack of response to or an inability to tolerate dextroamphetamine AND methylphenidate. Note: See also Multiple Sclerosis Drugs Duration of Approval: 2 years (Initials and Renewals) EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 104, record 63, corpus 2025-01-01; name match only, not an eligibility decision Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Modafinil Brand(s): Alertec DOSAGE FORM/ STRENGTH: 100 mg tablet For the treatment of fatigue in patients with multiple sclerosis who have demonstrated a lack of response to or an inability to tolerate amantadine. Note: See additional indications and criteria under “CNS” drugs Duration of Approval: Lifetime EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 231, record 136, corpus 2025-01-01; name match only, not an eligibility decision

How long EAP takes

Turnaround times The Exceptional Access Program receives between 250 and 500 requests a day. Requests are categorized in order of priority based on how quickly a drug is needed, the type of drug, and the condition for which the drug is being used. Turnaround times begin on the business day on which the EAP receives a complete request from a physician or nurse practitioner. You may have to wait longer if the request is missing information or supporting documents required by the EAP criteria, if a request requires external review, or if documents are sent by fax or mail instead of submitted via SADIE. EAP Weekly Progress Report Date: September 15, 2026 Processing categories and examples | Target | Current | Priority 1 — for drugs such as antibiotics, cancer medications, and initial requests for pain medications | 3 business days | 2 business day | Priority 2 — for antiviral drugs to treat HIV, drugs for multiple sclerosis, and pulmonary hypertension | 5 business days | 3 business days | Biologics — for biologic drugs to treat rheumatoid arthritis, psoriatic arthritis, ulcerative colitis and Crohn’s disease | 10 business days | 4 business days | Chronic — for drugs used for chronic conditions such as migraines, chronic pain, Ménière's disease and symptoms of Parkinson’s disease. | 4 to 6 weeks | 11 business days | (ontario.ca, Updated September 15, 2026 ↗) For selected drugs, the Telephone Request Service is available to authorized prescribers or their delegates. In most cases, the funding decision is provided by the end of the call and processed within one business day. (ontario.ca, Updated September 15, 2026 ↗)

1 brand, same coverage

Alertec · DIN 02239665 Manufacturer: Draxis Health Inc.; listing date 2008-06-27 Health Canada: Marketed since 2026-07-23 · brand ALERTEC · ATC N06BA07 MODAFINIL · form Tablet · route Oral · ingredients MODAFINIL 100 MG · company Neuraxpharm pharmaceuticals, s.l. · schedule Prescription

Check this DIN again · Health Canada product record

Ministry pays: $0.9293 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63139 · Verify on the e-Formulary ↗ (DIN 02239665)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02239665). DIN 02239665: Alertec Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 282000040; group id 518; item number 1405; lccId None; manufacturer id BJH Source form: Tab; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $1.8270; ministry $0.9293 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02239665 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=63139

Interchangeable products

Apo-Modafinil · DIN 02285398 · $0.9293 Auro-Modafinil · DIN 02430487 · $0.9293 Jamp Modafinil · DIN 02503727 · $0.9293 Mar-Modafinil · DIN 02432560 · $0.9293 Modafinil · DIN 02530244 · $0.9293 Teva-Modafinil · DIN 02420260 · $0.9293

Shortage status: discontinued (2023-06-14, reported by TEVA CANADA LIMITED); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02239665

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Modafinil · DIN 02285398 · 100mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-20

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Alertec; DOSAGE FORM/ STRENGTH: 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Modafinil Brand(s): Alertec DOSAGE FORM/ STRENGTH: 100 mg tablet For the symptomatic treatment of excessive daytime sleepiness in patients with narcolepsy who have demonstrated a lack of response to or an inability to tolerate dextroamphetamine AND methylphenidate. Note: See also Multiple Sclerosis Drugs Duration of Approval: 2 years (Initials and Renewals) EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 104, record 63, corpus 2025-01-01; name match only, not an eligibility decision Exceptional Access criteria on record are for Brand(s): Alertec; DOSAGE FORM/ STRENGTH: 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Modafinil Brand(s): Alertec DOSAGE FORM/ STRENGTH: 100 mg tablet For the treatment of fatigue in patients with multiple sclerosis who have demonstrated a lack of response to or an inability to tolerate amantadine. Note: See additional indications and criteria under “CNS” drugs Duration of Approval: Lifetime EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 231, record 136, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Apo-Modafinil · DIN 02285398 Manufacturer: Apotex Inc.; listing date 2008-06-27 Health Canada: Marketed since 2014-09-19 · brand APO-MODAFINIL · ATC N06BA07 MODAFINIL · form Tablet · route Oral · ingredients MODAFINIL 100 MG · company Apotex inc · schedule Prescription

Check this DIN again · Health Canada product record

Apo-Modafinil: Formulary list price $0.9293/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9293 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77089 · Verify on the e-Formulary ↗ (DIN 02285398)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02285398). DIN 02285398: Apo-Modafinil Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 282000040; group id 518; item number 1405; lccId None; manufacturer id APX Source form: Tab; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.9293; ministry $0.9293 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02285398 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77089

Interchangeable products

Alertec · DIN 02239665 · $0.9293 Auro-Modafinil · DIN 02430487 · $0.9293 Jamp Modafinil · DIN 02503727 · $0.9293 Mar-Modafinil · DIN 02432560 · $0.9293 Modafinil · DIN 02530244 · $0.9293 Teva-Modafinil · DIN 02420260 · $0.9293

Shortage status: resolved shortage (ended 2025-04-03); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02285398

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Modafinil · DIN 02430487 · 100mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-20

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Alertec; DOSAGE FORM/ STRENGTH: 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Modafinil Brand(s): Alertec DOSAGE FORM/ STRENGTH: 100 mg tablet For the symptomatic treatment of excessive daytime sleepiness in patients with narcolepsy who have demonstrated a lack of response to or an inability to tolerate dextroamphetamine AND methylphenidate. Note: See also Multiple Sclerosis Drugs Duration of Approval: 2 years (Initials and Renewals) EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 104, record 63, corpus 2025-01-01; name match only, not an eligibility decision Exceptional Access criteria on record are for Brand(s): Alertec; DOSAGE FORM/ STRENGTH: 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Modafinil Brand(s): Alertec DOSAGE FORM/ STRENGTH: 100 mg tablet For the treatment of fatigue in patients with multiple sclerosis who have demonstrated a lack of response to or an inability to tolerate amantadine. Note: See additional indications and criteria under “CNS” drugs Duration of Approval: Lifetime EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 231, record 136, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Auro-Modafinil · DIN 02430487 Manufacturer: Auro Pharma Inc.; listing date 2014-12-18 Health Canada: Marketed since 2014-10-24 · brand AURO-MODAFINIL · ATC N06BA07 MODAFINIL · form Tablet · route Oral · ingredients MODAFINIL 100 MG · company Auro pharma inc · schedule Prescription

Check this DIN again · Health Canada product record

Auro-Modafinil: Formulary list price $0.9293/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9293 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91494 · Verify on the e-Formulary ↗ (DIN 02430487)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02430487). DIN 02430487: Auro-Modafinil Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 282000040; group id 518; item number 1405; lccId None; manufacturer id AUR Source form: Tab; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.9293; ministry $0.9293 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02430487 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91494

Interchangeable products

Alertec · DIN 02239665 · $0.9293 Apo-Modafinil · DIN 02285398 · $0.9293 Jamp Modafinil · DIN 02503727 · $0.9293 Mar-Modafinil · DIN 02432560 · $0.9293 Modafinil · DIN 02530244 · $0.9293 Teva-Modafinil · DIN 02420260 · $0.9293

Shortage status: resolved shortage (ended 2024-09-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02430487

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp Modafinil · DIN 02503727 · 100mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Alertec; DOSAGE FORM/ STRENGTH: 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Modafinil Brand(s): Alertec DOSAGE FORM/ STRENGTH: 100 mg tablet For the symptomatic treatment of excessive daytime sleepiness in patients with narcolepsy who have demonstrated a lack of response to or an inability to tolerate dextroamphetamine AND methylphenidate. Note: See also Multiple Sclerosis Drugs Duration of Approval: 2 years (Initials and Renewals) EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 104, record 63, corpus 2025-01-01; name match only, not an eligibility decision Exceptional Access criteria on record are for Brand(s): Alertec; DOSAGE FORM/ STRENGTH: 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Modafinil Brand(s): Alertec DOSAGE FORM/ STRENGTH: 100 mg tablet For the treatment of fatigue in patients with multiple sclerosis who have demonstrated a lack of response to or an inability to tolerate amantadine. Note: See additional indications and criteria under “CNS” drugs Duration of Approval: Lifetime EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 231, record 136, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Jamp Modafinil · DIN 02503727 Manufacturer: Jamp Pharma Corporation; listing date 2021-04-30 Health Canada: Marketed since 2021-03-11 · brand JAMP MODAFINIL · ATC N06BA07 MODAFINIL · form Tablet · route Oral · ingredients MODAFINIL 100 MG · company Jamp pharma corporation · schedule Prescription

Check this DIN again · Health Canada product record

Jamp Modafinil: Formulary list price $0.9293/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9293 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99317 · Verify on the e-Formulary ↗ (DIN 02503727)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02503727). DIN 02503727: Jamp Modafinil Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 282000040; group id 518; item number 1405; lccId None; manufacturer id JPC Source form: Tab; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.9293; ministry $0.9293 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02503727 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99317

Interchangeable products

Alertec · DIN 02239665 · $0.9293 Apo-Modafinil · DIN 02285398 · $0.9293 Auro-Modafinil · DIN 02430487 · $0.9293 Mar-Modafinil · DIN 02432560 · $0.9293 Modafinil · DIN 02530244 · $0.9293 Teva-Modafinil · DIN 02420260 · $0.9293

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02503727

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Modafinil · DIN 02432560 · 100mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Alertec; DOSAGE FORM/ STRENGTH: 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Modafinil Brand(s): Alertec DOSAGE FORM/ STRENGTH: 100 mg tablet For the symptomatic treatment of excessive daytime sleepiness in patients with narcolepsy who have demonstrated a lack of response to or an inability to tolerate dextroamphetamine AND methylphenidate. Note: See also Multiple Sclerosis Drugs Duration of Approval: 2 years (Initials and Renewals) EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 104, record 63, corpus 2025-01-01; name match only, not an eligibility decision Exceptional Access criteria on record are for Brand(s): Alertec; DOSAGE FORM/ STRENGTH: 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Modafinil Brand(s): Alertec DOSAGE FORM/ STRENGTH: 100 mg tablet For the treatment of fatigue in patients with multiple sclerosis who have demonstrated a lack of response to or an inability to tolerate amantadine. Note: See additional indications and criteria under “CNS” drugs Duration of Approval: Lifetime EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 231, record 136, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Mar-Modafinil · DIN 02432560 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2015-01-28 Health Canada: Marketed since 2015-01-09 · brand MAR-MODAFINIL · ATC N06BA07 MODAFINIL · form Tablet · route Oral · ingredients MODAFINIL 100 MG · company Marcan pharmaceuticals inc · schedule Prescription

Check this DIN again · Health Canada product record

Mar-Modafinil: Formulary list price $0.9293/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9293 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91701 · Verify on the e-Formulary ↗ (DIN 02432560)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02432560). DIN 02432560: Mar-Modafinil Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 282000040; group id 518; item number 1405; lccId None; manufacturer id MAR Source form: Tab; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.9293; ministry $0.9293 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02432560 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=91701

Interchangeable products

Alertec · DIN 02239665 · $0.9293 Apo-Modafinil · DIN 02285398 · $0.9293 Auro-Modafinil · DIN 02430487 · $0.9293 Jamp Modafinil · DIN 02503727 · $0.9293 Modafinil · DIN 02530244 · $0.9293 Teva-Modafinil · DIN 02420260 · $0.9293

Shortage status: resolved shortage (ended 2018-10-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02432560

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Modafinil · DIN 02530244 · 100mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-20

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Alertec; DOSAGE FORM/ STRENGTH: 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Modafinil Brand(s): Alertec DOSAGE FORM/ STRENGTH: 100 mg tablet For the symptomatic treatment of excessive daytime sleepiness in patients with narcolepsy who have demonstrated a lack of response to or an inability to tolerate dextroamphetamine AND methylphenidate. Note: See also Multiple Sclerosis Drugs Duration of Approval: 2 years (Initials and Renewals) EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 104, record 63, corpus 2025-01-01; name match only, not an eligibility decision Exceptional Access criteria on record are for Brand(s): Alertec; DOSAGE FORM/ STRENGTH: 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Modafinil Brand(s): Alertec DOSAGE FORM/ STRENGTH: 100 mg tablet For the treatment of fatigue in patients with multiple sclerosis who have demonstrated a lack of response to or an inability to tolerate amantadine. Note: See additional indications and criteria under “CNS” drugs Duration of Approval: Lifetime EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 231, record 136, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Modafinil · DIN 02530244 Manufacturer: Sanis Health Inc.; listing date 2023-01-31 Health Canada: Marketed since 2022-12-19 · brand MODAFINIL · ATC N06BA07 MODAFINIL · form Tablet · route Oral · ingredients MODAFINIL 100 MG · company Sanis health inc · schedule Prescription

Check this DIN again · Health Canada product record

Modafinil: Formulary list price $0.9293/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9293 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101944 · Verify on the e-Formulary ↗ (DIN 02530244)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02530244). DIN 02530244: Modafinil Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 282000040; group id 518; item number 1405; lccId None; manufacturer id SAI Source form: Tab; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.9293; ministry $0.9293 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02530244 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101944

Interchangeable products

Alertec · DIN 02239665 · $0.9293 Apo-Modafinil · DIN 02285398 · $0.9293 Auro-Modafinil · DIN 02430487 · $0.9293 Jamp Modafinil · DIN 02503727 · $0.9293 Mar-Modafinil · DIN 02432560 · $0.9293 Teva-Modafinil · DIN 02420260 · $0.9293

Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02530244

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Modafinil · DIN 02420260 · 100mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02

Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives

Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.

Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. Current criteria in SADIE

Coverage criteria

Exceptional Access criteria on record are for Brand(s): Alertec; DOSAGE FORM/ STRENGTH: 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Modafinil Brand(s): Alertec DOSAGE FORM/ STRENGTH: 100 mg tablet For the symptomatic treatment of excessive daytime sleepiness in patients with narcolepsy who have demonstrated a lack of response to or an inability to tolerate dextroamphetamine AND methylphenidate. Note: See also Multiple Sclerosis Drugs Duration of Approval: 2 years (Initials and Renewals) EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 104, record 63, corpus 2025-01-01; name match only, not an eligibility decision Exceptional Access criteria on record are for Brand(s): Alertec; DOSAGE FORM/ STRENGTH: 100 mg tablet — not this product; no criteria on record for this product in this block. Exceptional Access Program criteria on record (ministry list dated 2025-01-01, not exhaustive): Ministry criteria list dated January 1, 2025; the program's current criteria may differ; SADIE shows the current version. https://www.ontario.ca/page/sadie-special-authorization-digital-information-exchange Modafinil Brand(s): Alertec DOSAGE FORM/ STRENGTH: 100 mg tablet For the treatment of fatigue in patients with multiple sclerosis who have demonstrated a lack of response to or an inability to tolerate amantadine. Note: See additional indications and criteria under “CNS” drugs Duration of Approval: Lifetime EAP source: eap-frequently-requested-drugs-2025-01-01.txt, page 231, record 136, corpus 2025-01-01; name match only, not an eligibility decision

Brand vs generic price

Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)

1 brand, same coverage

Teva-Modafinil · DIN 02420260 Manufacturer: Teva Canada Limited; listing date 2014-09-25 Health Canada: Marketed since 2014-07-02 · brand TEVA-MODAFINIL · ATC N06BA07 MODAFINIL · form Tablet · route Oral · ingredients MODAFINIL 100 MG · company Teva canada limited · schedule Prescription

Check this DIN again · Health Canada product record

Teva-Modafinil: Formulary list price $0.9293/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.9293 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90485 · Verify on the e-Formulary ↗ (DIN 02420260)

Source record

The source extract's flag for this DIN is unclear — confirm on the e-Formulary before prescribing (DIN 02420260). DIN 02420260: Teva-Modafinil Raw flags: sec3=Y, sec3b=Y, sec3bEAP=Y Item: 282000040; group id 518; item number 1405; lccId None; manufacturer id TEV Source form: Tab; strength: 100mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit; may be reimbursed through the Exceptional Access Program when approved (likely, unconfirmed) Source prices (unrounded): $0.9293; ministry $0.9293 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02420260 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90485

Interchangeable products

Alertec · DIN 02239665 · $0.9293 Apo-Modafinil · DIN 02285398 · $0.9293 Auro-Modafinil · DIN 02430487 · $0.9293 Jamp Modafinil · DIN 02503727 · $0.9293 Mar-Modafinil · DIN 02432560 · $0.9293 Modafinil · DIN 02530244 · $0.9293

Shortage status: resolved shortage (ended 2026-06-24); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02420260

Shortage record checked 2026-09-13T08:10:21.292534+00:00

Look up one drug

MODAFINIL

Alertec · DIN 02239665 · 100mg · tablet

Apo-Modafinil · DIN 02285398 · 100mg · tablet

Auro-Modafinil · DIN 02430487 · 100mg · tablet

Jamp Modafinil · DIN 02503727 · 100mg · tablet

Mar-Modafinil · DIN 02432560 · 100mg · tablet

Modafinil · DIN 02530244 · 100mg · tablet

Teva-Modafinil · DIN 02420260 · 100mg · tablet

Matched class: 28:20 C.N.S. Stimulants

DEXTROAMPHETAMINE SULFATE

LISDEXAMFETAMINE DIMESYLATE

METHYLPHENIDATE HCL

MIXED SALT AMPHETAMINE

Availability

Prepare an Exceptional Access request

Modafinil (Alertec)

Modafinil (Alertec)

Other review policies